Caption Management’s Immunovant IMVT Stock Holding History

Caption Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,000	Closed	-$407K	–	1781
2025 Q4	$407K	Sell	16,000 -74,000	-82%	-$1.65M	﹤0.01%	1272
2025 Q3	$1.45M	Buy	90,000 +57,924	+181%	+$938K	0.01%	967
2025 Q2	$513K	Buy	+32,076	New	+$485K	0.01%	1106
2025 Q1	–	Sell	-86,760	Closed	-$1.81M	–	1768
2024 Q4	$2.15M	Sell	86,760 -35,951	-29%	-$1.02M	0.02%	666
2024 Q3	$3.5M	Buy	122,711 +95,275	+347%	+$2.81M	0.06%	389
2024 Q2	$724K	Sell	27,436 -86,041	-76%	-$2.45M	0.01%	733
2024 Q1	$3.67M	Buy	+113,477	New	+$4.14M	0.06%	369
2023 Q4	–	Sell	-4,282	Closed	-$158K	–	1494
2023 Q3	$164K	Buy	+4,282	New	+$96.8K	﹤0.01%	1114
2021 Q2	–	Sell	-8,600	Closed	-$120K	–	1425
2021 Q1	$138K	Buy	+8,600	New	+$227K	﹤0.01%	945

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Caption Management's IMVT Position: Q1 2026 in Review

Caption Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 16,000 shares — an estimated $407K sold.

Caption Management first reported a position in IMVT in Q1 2021 and held it in 9 quarters. The position peaked at $3.67M in Q1 2024. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Caption Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
Caption Management sold 16,000 Immunovant shares in Q1 2026, an estimated $407K.
Caption Management first reported a position in Immunovant in Q1 2021 and held it in 9 quarters.
Caption Management's Immunovant position peaked at $3.67M in Q1 2024.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.